07.25.17
Novartis has signed an agreement contracting Cryoport for an initial three-year term for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy. In March, Novartis’ BLA for CTL019 was accepted by the FDA and was also granted priority review.
Cryoport will support Novartis' expanding cryogenic logistics requirements, including the use of its Cryoport Express shippers, SmartPak II Condition Monitoring System, Cryoportal Logistics Management Platform, which includes chain-of-condition and chain-of-custody monitoring and, 24/7/365 logistics support.
Jerrell Shelton, chief executive officer of Cryoport, said, "We are proud that Novartis has chosen Cryoport to support the clinical studies and the commercialization of its CLT019. This is a milestone for Cryoport. Our Novartis agreement is a good example of how our clinical trial agreements with biopharma clients can drive substantial revenue growth for Cryoport as therapies move through the stages of clinical trials to commercialization. Currently, we are supporting over 140 clinical trials in the regenerative medicine space with 17 of these biopharma clients in Phase III. We enjoy meeting Novartis's exacting requirements and are delighted to have this commercial agreement in place."
Cryoport will support Novartis' expanding cryogenic logistics requirements, including the use of its Cryoport Express shippers, SmartPak II Condition Monitoring System, Cryoportal Logistics Management Platform, which includes chain-of-condition and chain-of-custody monitoring and, 24/7/365 logistics support.
Jerrell Shelton, chief executive officer of Cryoport, said, "We are proud that Novartis has chosen Cryoport to support the clinical studies and the commercialization of its CLT019. This is a milestone for Cryoport. Our Novartis agreement is a good example of how our clinical trial agreements with biopharma clients can drive substantial revenue growth for Cryoport as therapies move through the stages of clinical trials to commercialization. Currently, we are supporting over 140 clinical trials in the regenerative medicine space with 17 of these biopharma clients in Phase III. We enjoy meeting Novartis's exacting requirements and are delighted to have this commercial agreement in place."